Use of “Western” medicines by location, age range, and length of time since diagnosis.

DM = diabetes mellitus, N = number of participants, NGT = normal glucose tolerance, undef = undefined.ap≤0.05 for urban vs. rural difference.bp≤0.05 for age.cp≤0.05 for duration of diabetes.dp≤0.05 for overall DM vs. NGT difference. General Notes1) Data based on self-reports of the medicines that each participant using at the time of the interview.2) Difference was defined as the rate for participants with DM minus the rate for participants with NGT.3) Ratio was defined as the rate for participants with DM divided by the rate for participants with NGT.4) Western medicines were defined as all medicines except traditional Chinese medicines.5) Results as displayed unadjusted except for the NGT values in the column labeled “All Participants/Adjusted.” In this column, adjusted values for participants with NGT were directly standardized to the age-sex distribution of participants with DM.6) P-values ≤0.05 include values ≤0.017) When not displayed, the rate for a participant with NGT can be calculated by dividing the rate for participants with DM by the DM:NGT ratio.

缩写说明：糖尿病（diabetes mellitus, DM）、受试者例数（number of participants, N）、糖耐量正常（normal glucose tolerance, NGT）、未定义（undefined, undef）。
各上标显著性标注如下：
a. 城乡组间差异的P值≤0.05；
b. 年龄因素的P值≤0.05；
c. 糖尿病病程相关的P值≤0.05；
d. 糖尿病组与糖耐量正常组总体差异的P值≤0.05。

通用说明：
1) 本数据集基于受试者在访谈时自行报告的当前用药情况；
2) 差值定义为糖尿病组受试者的对应率减去糖耐量正常组受试者的对应率；
3) 比值定义为糖尿病组受试者的对应率除以糖耐量正常组受试者的对应率；
4) 西药指除中药以外的所有药物；
5) 除标注为"所有受试者/校正"的列中的糖耐量正常组数值外，其余结果均未进行校正。该列中糖耐量正常组的校正值已直接按糖尿病组的年龄-性别分布进行标化；
6) P值≤0.05的范围包含≤0.01的情况；
7) 若未直接给出糖耐量正常组的对应率，可通过糖尿病组的对应率除以糖尿病组与糖耐量正常组的比值计算得到。